NEUROPHARMACOLOGY AND NEUROTOXICOLOGYInjections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adultsZaltzman, Roy; Beni, Sara M.1; Giladi, Eliezer; Pinhasov, Albert; Steingart, Ruth A.; Romano, Jacob; Shohami, Esther1; Gozes, IllanaCAAuthor Information Department of Clinical Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv 69978 1Department of Pharmacology, Hadassah Medical Centre, Hebrew University, Jerusalem, Israel CACorresponding Author: email@example.com Received 22 May 2002; accepted 30 June 2002 NeuroReport: March 3rd, 2003 - Volume 14 - Issue 3 - p 481-484 Buy Abstract The prophylactic neuroprotective effects of NAP, a femtomolar-acting neuroprotective peptide were tested in a mouse model of head trauma. NAP was injected for the first 3 weeks of life and head injury was initiated at 4 months. After trauma, mice were tested for their performance by evaluating damaged motor ability, balance and alertness. Comparison of the performance 1 h and 1 week after injury indicated that NAP treatment resulted in faster and enhanced recovery. In a 5-day Morris water maze test with mice suffering moderate to severe injuries, only the NAP-treated group learned to find the hidden platform in the maze. Furthermore, NAP treatment resulted in decreased mRNA expression of the inflammation marker, Mac-1. Thus, a potentially new prophylactic treatment against neurodegeneration is suggested. © 2003 Lippincott Williams & Wilkins, Inc.